Pharmaceutical Preparations
A source-attributed, AI-written analyst report for LLY.
Every figure is drawn from public filings — the AI writes the analysis, never the numbers.
How the company returns cash to shareholders — from its latest annual SEC filings.
Annual figures from SEC filings · descriptive, not a dividend-safety rating or advice. Delayed data.
Daily OHLC · MA/MACD/RSI computed locally. Not investment advice.
Reference figures from the latest SEC filings (FY2025).
| Market cap | $1.15T |
|---|---|
| P/E (TTM) | 43.2 |
| P/B | 36.72 |
| Dividend yield | 0.47% |
| Revenue (TTM) | $72.25B |
| Rev. growth (YoY) | +44.7% |
| Net income (TTM) | $25.28B |
| Net margin (TTM) | 35.0% |
| EPS, diluted (TTM) | $28.15 |
| 52-week range | $623.78 – $1249.45 |
| Next earnings | Aug 5, 2026 |
Figures from SEC filings · delayed prices · for reference only · not investment advice
Try one backtest free — see how the golden-cross signal performed on this stock.
Sign in to run a free backtestHistorical statistic over past daily data — how this rule behaved before, not a prediction or advice.
Trailing return vs the S&P 500 (SPY) — positive means it outperformed the market.
Trailing price performance vs SPY — a disclosed historical statistic, not a forecast or advice. Delayed data.
How the price has historically moved around past earnings announcements.
A ~2-session move spanning each earnings date — a disclosed historical statistic, not a forecast or advice. Delayed data.
Percentile rank vs Tickwind’s tracked universe — higher = stronger on that factor.
Percentile rank vs Tickwind’s tracked universe. The letter grades are a plain relabeling of these descriptive percentiles; the headline Quant Rating is a disclosed mechanical mapping of the composite percentile — a relative quantitative signal, not personalized investment advice. Delayed data.
Two published academic scores computed from SEC filings — itemized, descriptive, not a rating.
Computed from SEC XBRL filings via published academic formulas (Piotroski 2000; Altman 1968). Zone names are the papers’ published band labels. Descriptive — not a rating, prediction, or investment advice.
Average return by calendar month over the available years.
Historical average monthly returns — a disclosed statistic, not a forecast or advice. Delayed data.
Log in to track LLY and save links
Keep a watchlist and clip posts from anywhere — free.
Latest SEC filings and headlines for ELI LILLY & Co (LLY).
Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause
Yahoo · Jun 7, 2026
Dow Jones Futures Due Amid Market Rally's First Real Test; SpaceX IPO, Apple, Oracle Ahead
Yahoo · Jun 7, 2026
80% of Wegovy Pill Users Never Took a Weight Loss Drug Before. Does This Number Change the Entire Novo Nordisk Bear Case?
Yahoo · Jun 7, 2026
Figures from SEC filings · delayed prices · for reference only · not investment advice